MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the passing of Director Gary Brukardt on Tuesday, August 21, 2012. Mr. Brukardt, age 66, had served on the Company’s Board of Directors since 2006 and was a member of the Audit Committee and the Nominating and Corporate Governance Committee.
